Proteins are essential for good health; people affected by genetic disorders cannot produce these proteins. Examples of such proteins include insulin, various blood clotting factors, growth hormones and others. Protein therapy ensures efficient administration of these proteins to patients suffering from deficiency, resulting in effective therapeutic benefits. It is a type of medical treatment that possesses therapeutic effects in many diseases such as diabetes, brain diseases and cancer. Protein therapeutics are classified functionally into five major groups-
- Group I: Protein therapeutics with enzymatic or regulatory activity
- Group II: Protein therapeutics with special targeting activity
- Group III: Protein vaccines
- Group IV: Protein diagnostics
The protein therapeutics market presents immense potential due to its untapped market potential and wide range of application areas. More than 100 modified therapeutic proteins have been approved for clinical use in the U.S. and European Union. At present there are various protein therapeutics in development based on their pharmacological activity, molecular mechanism of activity and their molecular types.
For Technological breakthroughs, Value chain and stakeholder analysis Get Brochure: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2035
The protein therapeutics market can also be segmented based on product type, indication areas and geographies. The product segment includes monoclonal antibodies (mAbs), insulin, interferon, blood clotting factors and others. The various indication areas include diabetes, cancer, neurological disorders, genetic disorders and other indications. The major factors driving the protein therapeutics market are the increasing incidence of various chronic disorders such as cardiovascular, cancer and diabetes etc. and enhanced investments for the development of novel and efficient drugs. Moreover, rising number of medical insurance services and increased outsourcing of drug development processes are also expected to boost market growth. Increased awareness and high efficiency of these therapeutics with minimal side effects results in high acceptance levels by the end users. The major challenges of this market refer to the development of efficient methodologies to study the complex biological systems, catering to the individual variations and others including resistance to therapy and ensuring target efficiency.
Patent expirations of top selling protein therapeutics may mask the growth of the market. Some of the leading manufacturers of protein therapeutics are Roche Group, Sanofi, Eli Lilly & Company, Johnson & Johnson, Novartis, Bristol Myers Squibb Co., Pfizer, Inc., Amgen, Inc., and Merck Sereno S.A.